Page last updated: 2024-12-08
ro 12-5637
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
Ro 12-5637: metabolite of moclobemide [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 163052 |
SCHEMBL ID | 7640103 |
MeSH ID | M0173953 |
Synonyms (15)
Synonym |
---|
64544-24-7 |
4-chloro-n-[2-(4-oxidomorpholin-4-ium-4-yl)ethyl]benzamide |
4-chloranyl-n-[2-(4-oxidanidylmorpholin-4-ium-4-yl)ethyl]benzamide |
A837738 |
4-chloro-n-[2-(4-oxido-4-morpholin-4-iumyl)ethyl]benzamide |
ro-12-5637 |
benzamide, 4-chloro-n-(2-(4-morpholinyl)ethyl)-, n-oxide |
ro 12-5637 |
SCHEMBL7640103 |
DTXSID20983169 |
4-chloro-n-[2-(4-oxo-1,4lambda~5~-oxazinan-4-yl)ethyl]benzamide |
moclobemide n-oxide |
benzamide, 4-chloro-n-[2-(4-oxido-4-morpholinyl)ethyl]-; benzamide, 4-chloro-n-[2-(4-morpholinyl)ethyl]-, n-oxide; 4-chloro-n-[2-(4-oxido-4-morpholinyl)ethyl]benzamide; ro 12-5637; moclobemide n-oxide |
HY-135265 |
AKOS040753776 |
Research Excerpts
Pharmacokinetics
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 4 (80.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.87
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.87) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (20.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 4 (80.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |